$115.79
Today
as of Jul 22, 16:50 ET
Last 30 days
Recent Press Releases & News
Morgan Stanley Adjusts Price Target on Incyte to $104 From $103, Maintains Equalweight Rating
HALO Inks Deal With INCY to Support Cancer Therapy Development
Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth
Overview
52-week range
$67
$112
100% of range
Avg surprise (last 2)
+16.8%
Avg reaction (last 1)
+1.5%
100% positive
Latest IV / EM
36%
EM ±8.3% · $115 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Mar 31, 2026 | Mar 2026 | $1.47 | — | — | — | — | financials |
| Tue Sep 30, 2025 | Sep 2025 | $2.11 | — | — | — | — | financials |
| Tue Jul 29, 2025 | Jun/2025 | $1.31 | $1.14 | +14.9% | — | — | earnings |
| Tue Apr 29, 2025 | Mar/2025 | $0.89 | $0.75 | +18.7% | — | +1.5% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $0.54 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-2.04 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $0.75 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $0.76 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $0.90 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Tue Jul 28, 2026 | Jun/2026 | BMO | $1.61 | $1.31 | +22.9% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | $105M | — | $99M | $79M | $73M | — | $86M | $77M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $301M | — | $444M | $530M | $205M | — | $146M | $-478M |
| Net income | $303M | — | $424M | $405M | $158M | — | $106M | $-445M |
| EPS (diluted) | $1.47 | — | $2.11 | $2.04 | $0.80 | — | $0.54 | $-2.04 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $3.46B | $3.10B | $2.46B | $1.95B | $1.94B | $1.69B | $1.30B | $987M |
| Inventory | $116M | $101M | $83M | $83M | $64M | $59M | $70M | $101M |
| Total current assets | $5.48B | $5.02B | $4.28B | $3.64B | $3.51B | $3.24B | $2.81B | $2.57B |
| Total assets | $7.34B | $6.96B | $6.33B | $5.82B | $5.75B | $5.44B | $5.01B | $4.66B |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $1.72B | $1.79B | $1.68B | $1.65B | $2.08B | $2.00B | $1.84B | $1.66B |
| Total equity | $5.62B | $5.17B | $4.65B | $4.17B | $3.67B | $3.45B | $3.17B | $3.00B |